StockIQpro
NASDAQ:IOVA

Iovance Biotherapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Iovance Biotherapeutics, Inc.'s revenue grew 60.6% in fiscal 2025 to $263.5M while operating margin rose to −153.1%, its highest in 3 years. Free cash flow was −$336.2M, −127.6% of revenue, and the diluted share count rose 23.3%.Summary generated from Iovance Biotherapeutics, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$263.5M
Revenue growth+60.6%
Revenue, 5-yr CAGRn/a
Gross margin34.3%
Operating margin−153.1%
Net margin−148.4%
ROICn/a
Return on equity−55.5%
Debt / equityn/a
Free cash flow−$336.2M
FCF margin−127.6%
Share count change+23.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/a1164264
Operating income−343−399−461−395−403
Net income−342−396−444−372−391
Free cash flow−266−313−384−364−336

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)